98%
921
2 minutes
20
Biofilms present a significant obstacle in the treatment of bacterial infections, because of their ability to evade the host immune response and to resist conventional antibacterial drugs. This study introduces an innovative approach to overcoming these challenges by targeting the biofilm microenvironment using a multifunctional therapeutic platform. The platform leverages perfluorohexane (PFH) as an oxygen carrier to alleviate the multifunctional therapeutic platform. It combines the photosensitizer indium Chlorin e6 (Ce6) and the photothermal agent molybdenum disulfide (MoS) co-encapsulated within a liposome nanoparticle structure, further stabilized by Zeolitic imidazolate framework-8 (ZIF-8). This configuration, termed MoS-Ce6-PFH@ZIF-8 (MCP@ZIF-8) improves the stability, functionality, and therapeutic potential of the nanoparticles. Additionally, the nanoparticles are embedded into a hydrogel matrix (MCP@ZCP formed by cross-linking carboxymethyl chitosan (CMCS) with pluronic F-127 (PF-127) for localized delivery. MCP@ZIF-8 exhibited a high photothermal therapy conversion efficiency of approximately 52.7%, thereby enabling effective heat generation under near-infrared (NIR) light. MCP@ZIF-8 produced higher reactive oxygen species levels than Ce6 alone under NIR irradiation at 660 nm. This dual photothermal and photodynamic mechanism achieves an antibacterial efficacy of up to 99%, effectively disrupting biofilms. Animal studies demonstrated that MCP@ZCP promotes superior wound healing, compared with conventional treatments. Transcriptome analysis demonstrated that MCP@ZCP disrupts bacterial metabolic pathways including amino acid synthesis, carbon metabolism, nitrogen metabolism, and other pathways, thereby inhibiting bacterial growth and proliferation. Comprehensive biosafety assessments have confirmed that MCP@ZCP is biocompatible and nontoxic, indicating its suitability for clinical applications. Thus, oxygen-carrying hydrogels can be used as an approach for treating bacterial infections.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.5c11868 | DOI Listing |
J Appl Microbiol
September 2025
Sivas Cumhuriyet University, Faculty of Medicine, Department of Medical Microbiology, 58140 Sivas, Türkiye.
Aims: The increasing antimicrobial resistance, particularly in Acinetobacter baumannii, complicates the treatment of infections, leading to higher morbidity, mortality, and economic costs. Herein, we aimed to determine the in vitro antimicrobial, synergistic, and antibiofilm activities of colistin (COL), meropenem, and ciprofloxacin antibiotics, and curcumin, punicalagin, geraniol (GER), and linalool (LIN) plant-active ingredients alone and in combination against 31 multidrug-resistant (MDR) A. baumannii clinical isolates.
View Article and Find Full Text PDFJ Fish Dis
September 2025
Guangdong Provincial Water Environment and Aquatic Products Security Engineering Technology Research Center, Guangzhou Key Laboratory of Aquatic Animal Diseases and Waterfowl Breeding, College of Animal Sciences and Technology, Zhongkai University of Agriculture and Engineering, Guangzhou, Guangdong
Vibrio infections cause enteritis in grouper fish, leading to high mortality and stunted growth, which is a major challenge for aquaculture. Oligochitosans, marine prebiotics with bioactive properties, have proven their potential for growth promotion and immune regulation. However, the impacts of Vibrio harveyi on the gut microbiome of grouper fish and the potential of oligochitosans to modulate these effects remain poorly understood.
View Article and Find Full Text PDFEnviron Microbiol
September 2025
Listeria: Biology and Infection Research Group (LisBio), Valencia, Spain.
Listeria monocytogenes is a saprophytic bacterium and a foodborne pathogen of humans and animals. Little is known about its distribution and genetic diversity across different environments within the same geographical region. We conducted a large-scale longitudinal study in southeastern Spain monitoring Listeria spp.
View Article and Find Full Text PDFBasic Clin Pharmacol Toxicol
October 2025
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Helicobacter
September 2025
Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: Several clinical studies have demonstrated that Helicobacter pylori (Hp) infection may exacerbate the progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD); however, the underlying mechanisms remain unclear. This study aims to investigate the characterization of the gastric microbiome and metabolome in relation to the progression of MASLD induced by Hp infection.
Methods: We established a high-fat diet (HFD) obese mouse model, both with and without Hp infection, to compare alterations in serum and liver metabolic phenotypes.